Damora Therapeutics Files Definitive Proxy for Annual Meeting, Details New Executive Compensation & Auditor Change

summarizeSummary

Damora Therapeutics filed its definitive proxy statement for the 2026 Annual Meeting, outlining proposals for director elections, executive compensation, and auditor ratification, while also detailing the severance for the former CEO and compensation for the new executive team.

check_boxKey Events

• Annual Meeting Scheduled

  The 2026 Annual Meeting of Stockholders will be held virtually on Wednesday, June 17, 2026, at 9:00 a.m. Eastern Time. The record date for voting is April 22, 2026.

• Executive Leadership Transition Details

  The filing provides details on the appointment of Jennifer Jarrett as President and CEO (effective March 30, 2026), Becker Hewes as Chief Medical Officer (January 2026), and Sherwin Sattarzadeh as Chief Operating Officer (January 2026). It also outlines the severance package for former CEO Hans T. Schambye, whose employment was terminated without cause effective February 10, 2026, including 15 months of base salary, a pro-rata bonus, full equity acceleration, and an unpaid retention bonus.

• Auditor Change Ratification with Clarification

  Stockholders will vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. This follows the dismissal of EY Godkendt Revisionspartnerselskab on April 17, 2026, which was explicitly stated not to be due to any disagreements or reportable events, mitigating potential negative concerns.

• Director Nominees for Election

  Michael Landsittel and Cameron Turtle, D.Phil, who were appointed to the Board in March 2026, have been nominated for election as Class III directors for a three-year term expiring at the 2029 Annual Meeting.

auto_awesomeAnalysis

This definitive proxy statement provides a comprehensive overview of Damora Therapeutics' corporate governance, executive leadership, and compensation structure following its recent strategic pivot and name change. Key information includes the formal proposals for the upcoming annual meeting, such as the election of two new Class III directors. Notably, the filing details the significant executive leadership transition, including the appointment of Jennifer Jarrett as President and CEO and the severance package for former CEO Hans T. Schambye, which involves substantial cash and accelerated equity. The ratification of Ernst & Young LLP as the new independent auditor is also highlighted, with a crucial clarification that the change was not due to any disagreements or reportable events, which is a positive signal for investors.